Swanson Gregory P, Chen Wencong, Speights V O
Department of Radiation Oncology, Baylor Scott & White Healthcare, Temple TX, USA.
Department of Biostatistics, Baylor Scott & White Research Institute, Temple, TX, USA.
World J Oncol. 2018 Jun;9(3):69-73. doi: 10.14740/wjon1111w. Epub 2018 Jun 26.
Historically, ploidy and S phase percentage appeared to be promising predictors for prostate cancer recurrence. Lack of uniformity and consistency hampered their development. We evaluated ploidy and S phase for prostate cancer death in a cohort of patients with long-term follow-up.
We identified 127 patients that had ploidy and S phase determined at the time of their radical prostatectomy for prostate cancer. With 15 years of follow-up, we determined the risk of biochemical failure and risk of death from prostate cancer. We correlated the S phase and ploidy findings with standard pathology findings.
A total of 107 (84%) had diploid and 20 (16%) had non-diploid cancers. The median S phase was 6.6%. There was no correlation of ploidy (P = 0.472) or S phase with preoperative PSA or Gleason score. On univariate analysis, EPE, margin positivity, seminal vesicle involvement, lymph node involvement, high Gleason score and PSA > 10 ng/mL were all predictive of biochemical failure. Ploidy and S phase were not. For prostate cancer death, only Gleason score was predictive.
With long-term follow-up in our cohort, Gleason score was predictive of prostate cancer death. Ploidy and S phase were not predictive for biochemical failure or prostate cancer mortality.
从历史上看,倍体和S期百分比似乎是前列腺癌复发的有前景的预测指标。缺乏一致性和连贯性阻碍了它们的发展。我们在一组长期随访的患者中评估了倍体和S期与前列腺癌死亡的关系。
我们确定了127例在前列腺癌根治性前列腺切除术时测定了倍体和S期的患者。经过15年的随访,我们确定了生化失败的风险和前列腺癌死亡的风险。我们将S期和倍体的结果与标准病理结果进行了关联。
共有107例(84%)为二倍体癌,20例(16%)为非二倍体癌。S期的中位数为6.6%。倍体(P = 0.472)或S期与术前前列腺特异性抗原(PSA)或Gleason评分均无相关性。单因素分析显示,包膜外侵犯(EPE)、切缘阳性、精囊受累、淋巴结受累、高Gleason评分和PSA>10 ng/mL均为生化失败的预测因素。倍体和S期不是。对于前列腺癌死亡,只有Gleason评分具有预测性。
在我们的队列中进行长期随访,Gleason评分可预测前列腺癌死亡。倍体和S期对生化失败或前列腺癌死亡率无预测性。